Mirati Therapeutics

128 articles with Mirati Therapeutics

• Mirati Therapeutics To Present At Upcoming Healthcare Conferences

  3/5/2019

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences.

• Mirati Therapeutics Reports Fourth Quarter Financial Results

  2/28/2019

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018.

• Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors

  2/19/2019

  Mirati Therapeutics, Inc., a clinical stage targeted oncology company, announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019.

• Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

  2/7/2019

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at 11:00 a.m. ET/ 8:00 a.m. PT.

• Mirati Therapeutics Announces Closing Of Public Offering Of 1,854,838 Shares of Its Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

  1/22/2019

  Mirati Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62.00 per share.

• Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock - January 16, 2019

  1/17/2019

  Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share

• Lonza Announces Initiation of S&P Credit Rating with Investment Grade of BBB+ and Stable Outlook

  1/17/2019

  Lonza announced that Standard & Poor's (S&P) assigned a BBB+ credit rating with stable outlook to Lonza.

• Mirati Therapeutics Announces Proposed Public Offering Of Common Stock - January 16, 2019

  1/16/2019

  Mirati Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offering.

• Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock at $62.00 Per Share

  1/16/2019

  Mirati Therapeutics, Inc. (Nasdaq: MRTX) announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share.

• Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

  1/15/2019

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations.

• Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

  1/7/2019

   Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO®), in Mirati's planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.

• Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Mirati Therapeutics, Inc. will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9th at 8:00 a.m. PST/ 11:00 a.m. EST.

• Mirati Therapeutics Added To NASDAQ Biotechnology Index

  12/20/2018

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI).

• Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors

  12/10/2018

  Mirati Therapeutics, Inc. today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately.

• Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849

  11/29/2018

  Mirati Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for MRTX849, a small molecule inhibitor of KRAS G12C.  Mirati is developing MRTX849 for the treatment of cancers driven by KRAS G12C mutations. 

• Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference

  11/20/2018

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27th at 12:30 p.m. EST/ 9:30 a.m. PST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the conference.

• Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting

  11/9/2018

  Mirati Therapeutics, Inc. announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C.

• Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting

  11/9/2018

  Mirati Therapeutics, Inc. announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C.

• Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors

  11/8/2018

  Mirati Therapeutics, Inc. today announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in a Phase 1b clinical trial to assess the safety and tolerability, pharmacokinetics and preliminary anti-tumor activity of Mirati's sitravatinib in combination with BeiGene's investigational anti-PD1 antibody, tislelizumab, in patients with advanced solid tumors.

• Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference

  11/7/2018

  Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will present a corporate overview at the conference.